Pfizer Inc. $PFE Shares Bought by Capital International Sarl

Capital International Sarl increased its stake in shares of Pfizer Inc. (NYSE:PFE) by 6.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 418,615 shares of the biopharmaceutical company’s stock after acquiring an additional 25,031 shares during the quarter. Capital International Sarl’s holdings in Pfizer were worth $10,666,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Grey Fox Wealth Advisors LLC purchased a new stake in shares of Pfizer in the 3rd quarter valued at about $29,000. Howard Hughes Medical Institute acquired a new position in Pfizer during the second quarter worth approximately $30,000. True Wealth Design LLC boosted its holdings in shares of Pfizer by 302.5% in the third quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 974 shares during the period. Darwin Wealth Management LLC purchased a new position in shares of Pfizer during the second quarter worth approximately $32,000. Finally, Evelyn Partners Asset Management Ltd purchased a new stake in Pfizer in the 2nd quarter valued at $33,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Down 0.9%

PFE opened at $26.81 on Tuesday. The company has a market cap of $152.42 billion, a price-to-earnings ratio of 19.71 and a beta of 0.47. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16. Pfizer Inc. has a one year low of $20.92 and a one year high of $27.94. The business’s fifty day moving average is $26.34 and its two-hundred day moving average is $25.48.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.57 by $0.09. The business had revenue of $17.56 billion for the quarter, compared to analyst estimates of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The company’s quarterly revenue was down 1.2% on a year-over-year basis. During the same period in the prior year, the business earned $0.63 earnings per share. Analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, March 6th. Investors of record on Friday, January 23rd were paid a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.4%. The ex-dividend date was Friday, January 23rd. Pfizer’s dividend payout ratio is presently 126.47%.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the stock. Royal Bank Of Canada assumed coverage on shares of Pfizer in a research note on Tuesday, February 24th. They issued an “underperform” rating and a $25.00 price objective on the stock. Barclays started coverage on Pfizer in a research report on Thursday, February 19th. They issued an “underweight” rating and a $25.00 price target on the stock. TD Cowen reaffirmed a “hold” rating on shares of Pfizer in a research report on Tuesday, December 30th. Zacks Research raised Pfizer from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 24th. Finally, Citigroup started coverage on Pfizer in a report on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, fourteen have given a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $28.05.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.